Changes in Beneficial Ownership · 4
Beta Bionics, Inc.
BBNXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-09172026_040905.xml
Filing details
- Report period
- 2026-09-16
- Issuer
- Beta Bionics, Inc.
- Issuer CIK
- 0001674632
- Trading symbol
- BBNX
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Hopman Mark
- Reporting owner CIK
- 0002048497
- Relationship
- Officer
- Officer title
- Chief Commercial Officer
- Address
- C/O BETA BIONICS, INC., 11 HUGHES, IRVINE, CA, 92618
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-09-16 | S · Form 4[F1] | 30,779 | D | 20.1319[F2] | 56,479 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Footnotes
- F1
- Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on June 10, 2026.↩ 1
- F2
- The weighted average sale price for the transaction reported was $20.1319 and the range of prices were between $20.00 and $20.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.↩ 1
Signature 1
- Signed
- /s/ Stephen Feider, Attorney-in-Fact
- Date
- 2026-09-17
Company context
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an